{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:43:12Z","timestamp":1790646192479,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bcp.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T19:16:32Z","timestamp":1562354192000},"page":"305-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate"],"prefix":"10.1016","volume":"168","author":[{"given":"Jonasz Jeremiasz","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Emily","family":"Clemensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi Birgir","family":"Schi\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huu Phuc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.07.002_b0005","series-title":"Neurological Disorders: Public Health Challenges","author":"World Health Organization","year":"2006"},{"key":"10.1016\/j.bcp.2019.07.002_b0010","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41593-018-0221-2","article-title":"Selective vulnerability in neurodegenerative diseases","volume":"21","author":"Fu","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3654","article-title":"Rare diseases and orphan drugs","volume":"11","author":"Melnikova","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.07.002_b0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.23672","article-title":"Network the C and IC of the RDCR. Unintended effects of orphan product designation for rare neurological diseases","volume":"72","author":"Murphy","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2019.07.002_b0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: the need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcp.2019.07.002_b0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","article-title":"Orphan drugs and their impact on pharmaceutical development","volume":"39","author":"Attwood","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2019.07.002_b0035","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","article-title":"Gene therapy for neurodegenerative diseases","volume":"21","author":"O\u2019Connor","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcp.2019.07.002_b0040","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1089\/hum.2017.160","article-title":"Clinical gene therapy for neurodegenerative diseases: past, present, and future","volume":"28","author":"Piguet","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcp.2019.07.002_b0045","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41593-018-0237-7","article-title":"Converging pathways in neurodegeneration, from genetics to mechanisms","volume":"21","author":"Gan","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0050","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13023-018-0930-3","article-title":"Investigating the landscape of US orphan product approvals","volume":"13","author":"Miller","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcp.2019.07.002_b0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2019.07.002_b0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis","volume":"322","author":"Bordet","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.07.002_b0070","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1093\/brain\/awv290","article-title":"Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat","volume":"138","author":"Clemens","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2019.07.002_b0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bph.12939","article-title":"Protective role of olesoxime against wild-type \u03b1-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells","volume":"172","author":"Gouarn\u00e9","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2019.07.002_b0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/ph3020345","article-title":"Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound","volume":"3","author":"Bordet","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2019.07.002_b0085","first-page":"568","article-title":"Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis","volume":"13","author":"Martin","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/j.bcp.2019.07.002_b0090","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bcp.2010.04.018","article-title":"Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells","volume":"80","author":"Rovini","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2019.07.002_b0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/jpet.108.139410","article-title":"Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy","volume":"326","author":"Bordet","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.07.002_b0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ana.22593","article-title":"Olesoxime accelerates myelination and promotes repair in models of demyelination","volume":"71","author":"Magalon","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2019.07.002_b0105","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pain.2009.09.006","article-title":"Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel","volume":"147","author":"Xiao","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2019.07.002_b0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel","volume":"203","author":"Xiao","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2019.07.002_b0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12035-014-8663-3","article-title":"Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime","volume":"50","author":"Eckmann","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2019.07.002_b0120","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.neuropharm.2012.02.013","article-title":"Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model","volume":"62","author":"Sunyach","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2019.07.002_b0125","article-title":"The calpain-suppressing effects of olesoxime in Huntington\u2019s disease","volume":"4","author":"Weber","year":"2016","journal-title":"Rare Dis. (Austin, Tex.)"},{"key":"10.1016\/j.bcp.2019.07.002_b0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ene.12344","article-title":"A phase II\u2212III trial of olesoxime in subjects with amyotrophic lateral sclerosis","volume":"21","author":"Lenglet","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bcp.2019.07.002_b0135","first-page":"C78","article-title":"TRO19622 is well tolerated and target plasma concentrations are obtained at doses 250\/500 mg once a day in a one month ALS phase 1B, add-on to riluzole, clinical study","volume":"Abs","author":"Verschueren","year":"2007","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.bcp.2019.07.002_b0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neuropharm.2016.09.009","article-title":"Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules","volume":"111","author":"Magalon","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2019.07.002_b0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/35048073","article-title":"The mitochondrion in apoptosis: how Pandora\u2019s box opens","volume":"2","author":"Zamzami","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0150","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/bph.12094","article-title":"Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF","volume":"168","author":"Gouarn\u00e9","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2019.07.002_b0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ana.24070","article-title":"NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage","volume":"75","author":"Ma","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2019.07.002_b0160","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fphys.2017.00324","article-title":"Olesoxime inhibits cardioplegia-induced ischemia\/reperfusion injury. A study in langendorff-perfused rabbit hearts","volume":"8","author":"Salameh","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2019.07.002_b0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphys.2013.00095","article-title":"The mitochondrial permeability transition pore: a mystery solved?","volume":"4","author":"Bernardi","year":"2013","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2019.07.002_b0170","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.yjmcc.2009.02.021","article-title":"What is the mitochondrial permeability transition pore?","volume":"46","author":"Halestrap","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.bcp.2019.07.002_b0175","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1073\/pnas.1410104111","article-title":"Identifying the components of the elusive mitochondrial permeability transition pore","volume":"111","author":"Karch","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2019.07.002_b0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tem.2015.02.007","article-title":"The changing landscape in translocator protein (TSPO) function","volume":"26","author":"Selvaraj","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.07.002_b0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tibs.2015.07.001","article-title":"Enigmatic translocator protein (TSPO) and cellular stress regulation","volume":"40","author":"Batoko","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2019.07.002_b0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.mam.2010.03.002","article-title":"VDAC, a multi-functional mitochondrial protein regulating cell life and death","volume":"31","author":"Shoshan-Barmatz","year":"2010","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bcp.2019.07.002_b0195","first-page":"746","article-title":"Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases","volume":"5","author":"Vance","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bcp.2019.07.002_b0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.biocel.2012.06.009","article-title":"Mitochondria: Mitochondrial membranes in brain ageing and neurodegeneration","volume":"45","author":"Eckmann","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0205","doi-asserted-by":"crossref","first-page":"33928","DOI":"10.1074\/jbc.M210943200","article-title":"Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity","volume":"278","author":"Colell","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.07.002_b0210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.32607\/20758251-2016-8-1-58-73","article-title":"Brain cholesterol metabolism and its defects: linkage to neurodegenerative diseases and synaptic dysfunction","volume":"8","author":"Petrov","year":"2016","journal-title":"Acta Naturae"},{"key":"10.1016\/j.bcp.2019.07.002_b0215","first-page":"606","article-title":"Similar oxysterols may lead to opposite effects on synaptic transmission: Olesoxime versus 5\u03b1-cholestan-3-one at the frog neuromuscular junction","author":"Kasimov","year":"1861","journal-title":"Biochim. Biophys. Acta \u2013 Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.bcp.2019.07.002_b0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/rda.13060","article-title":"Voltage-dependent anion channel 2 is involved in in vitro capacitation of boar sperm","volume":"52","author":"Mart\u00ednez-Abad","year":"2017","journal-title":"Reprod. Domest. Anim."},{"key":"10.1016\/j.bcp.2019.07.002_b0225","doi-asserted-by":"crossref","first-page":"19098","DOI":"10.1074\/jbc.M114.571414","article-title":"Bacterial RTX toxins allow acute ATP release from human erythrocytes directly through the toxin pore","volume":"289","author":"Skals","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.07.002_b0230","doi-asserted-by":"crossref","first-page":"H553","DOI":"10.1152\/ajpheart.00998.2011","article-title":"Prostacyclin receptor-mediated ATP release from erythrocytes requires the voltage-dependent anion channel","volume":"302","author":"Sridharan","year":"2012","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"10.1016\/j.bcp.2019.07.002_b0235","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1529\/biophysj.107.105379","article-title":"Phosphorothioate oligonucleotides block the VDAC channel","volume":"93","author":"Tan","year":"2007","journal-title":"Biophys. J."},{"key":"10.1016\/j.bcp.2019.07.002_b0240","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.abb.2010.01.008","article-title":"Closure of VDAC causes oxidative stress and accelerates the Ca2+-induced mitochondrial permeability transition in rat liver mitochondria","volume":"495","author":"Tikunov","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2019.07.002_b0245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.abb.2015.10.012","article-title":"Combined effect of G3139 and TSPO ligands on Ca2+-induced permeability transition in rat brain mitochondria","volume":"587","author":"Azarashvili","year":"2015","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2019.07.002_b0250","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd.2016.212","article-title":"Calpain research for drug discovery: challenges and potential","volume":"15","author":"Ono","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.07.002_b0255","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.stem.2013.04.003","article-title":"A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS","volume":"12","author":"Yang","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2019.07.002_b0260","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1038\/s41598-019-39739-5","article-title":"A ferroptosis\u2013based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis","volume":"9","author":"Devos","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2019.07.002_b0265","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nm.2224","article-title":"The benefits and limitations of animal models for translational research in neurodegenerative diseases","volume":"16","author":"Jucker","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2019.07.002_b0270","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12844","article-title":"Why clinical translation cannot succeed without failure","volume":"4","author":"London","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2019.07.002_b0275","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/bja\/aet208","article-title":"Neuropathic pain in cancer","volume":"111","author":"Fallon","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.bcp.2019.07.002_b0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fnins.2017.00481","article-title":"A Mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fukuda","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0285","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0290","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clinthera.2013.11.006","article-title":"Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials","volume":"36","author":"Zanetta","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcp.2019.07.002_b0295","first-page":"90","article-title":"A long-term, open-label follow-up study of olesoxime in patients with Type 2 or non-ambulatory Type 3 spinal muscular atrophy who participated in a placebo-controlled Phase 2 trial (S46.002)","author":"Muntoni","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2019.07.002_b0300","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3109\/00207454.2013.804523","article-title":"TRO19622 promotes myelin repair in a rat model of demyelination","volume":"123","author":"Li","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0305","first-page":"84","article-title":"Results of a Phase 1b study to confirm safety and tolerability of olesoxime in multiple sclerosis patients (P7.282)","author":"Pelletier","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2019.07.002_b0310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nbd.2014.05.012","article-title":"Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons","volume":"69","author":"Richter","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2019.07.002_b0315","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1124\/jpet.110.167486","article-title":"TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition","volume":"333","author":"Schaller","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.07.002_b0320","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrneurol.2011.132","article-title":"Cholesterol metabolism in Huntington disease","volume":"7","author":"Karasinska","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2019.07.002_b0325","first-page":"1095","article-title":"The impairment of cholesterol metabolism in Huntington disease","author":"Leoni","year":"1851","journal-title":"Biochim. Biophys. Acta \u2013 Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.bcp.2019.07.002_b0330","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1523\/JNEUROSCI.3355-05.2005","article-title":"Dysfunction of the cholesterol biosynthetic pathway in Huntington\u2019s disease","volume":"25","author":"Valenza","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0335","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awv384","article-title":"CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington\u2019s disease","volume":"139","author":"Boussicault","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2019.07.002_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108674","article-title":"Cytoprotective effects of olesoxime on isolated human pancreatic islets in order to attenuate apoptotic pathway","volume":"112","author":"Kaviani","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2019.07.002_b0345","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/d41586-018-05719-4","article-title":"The amyloid hypothesis on trial","volume":"559","author":"Makin","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2019.07.002_b0350","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.2220","article-title":"Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future","volume":"16","author":"Lang","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2019.07.002_b0355","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2019.07.002_b0360","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphys.2017.00460","article-title":"Mitochondrial VDAC1: a key gatekeeper as potential therapeutic target","volume":"8","author":"Camara","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2019.07.002_b0365","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1210\/me.2015-1033","article-title":"Minireview: translocator protein (TSPO) and steroidogenesis: a reappraisal","volume":"29","author":"Selvaraj","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2019.07.002_b0370","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.4161\/15548627.2014.991665","article-title":"TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control","volume":"10","author":"Gatliff","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2019.07.002_b0375","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41386-018-0293-4","article-title":"TSPO upregulation in bipolar disorder and concomitant downregulation of mitophagic proteins and NLRP3 inflammasome activation","volume":"44","author":"Scaini","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2019.07.002_b0380","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ncb2012","article-title":"PINK1\/Parkin-mediated mitophagy is dependent on VDAC1 and p62\/SQSTM1","volume":"12","author":"Geisler","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0385","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4161\/auto.6.8.13426","article-title":"p62\/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both","volume":"6","author":"Narendra","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2019.07.002_b0390","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1042\/bj3580147","article-title":"Calcium binding and translocation by the voltage-dependent anion channel: a possible regulatory mechanism in mitochondrial function","volume":"358","author":"Gincel","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2019.07.002_b0395","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.186","article-title":"A role for TSPO in mitochondrial Ca2+ homeostasis and redox stress signaling","volume":"8","author":"Gatliff","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2019.07.002_b0400","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cvr\/cvs163","article-title":"Calpains, mitochondria, and apoptosis","volume":"96","author":"Smith","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2019.07.002_b0405","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.redox.2015.08.010","article-title":"Calcium and ROS: a mutual interplay","volume":"6","author":"G\u00f6rlach","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0410","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrm3412","article-title":"Mitochondria as sensors and regulators of calcium signalling","volume":"13","author":"Rizzuto","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0415","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1083\/jcb.200608073","article-title":"Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels","volume":"175","author":"Szabadkai","year":"2006","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0420","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.aan6009","article-title":"ER-mitochondria tethering by PDZD8 regulates Ca2+ dynamics in mammalian neurons","volume":"358","author":"Hirabayashi","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bcp.2019.07.002_b0425","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tins.2016.01.008","article-title":"There\u2019s something wrong with my MAM; the ER-mitochondria axis and neurodegenerative diseases","volume":"39","author":"Paillusson","year":"2016","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0430","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jphs.2014.07.001","article-title":"Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs","volume":"127","author":"Hayashi","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2019.07.002_b0435","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41580-018-0052-8","article-title":"The machineries, regulation and cellular functions of mitochondrial calcium","volume":"19","author":"Giorgi","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0440","doi-asserted-by":"crossref","first-page":"17076","DOI":"10.1038\/cddiscovery.2017.76","article-title":"Glucose-regulated protein 75 determines ER\u2013mitochondrial coupling and sensitivity to oxidative stress in neuronal cells","volume":"3","author":"Honrath","year":"2017","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2019.07.002_b0445","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1111\/febs.14366","article-title":"Inositol 1,4,5-trisphosphate receptors and neurodegenerative disorders","volume":"285","author":"Egorova","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2019.07.002_b0450","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1083\/jcb.200205091","article-title":"Recombinant expression of the voltage-dependent anion channel enhances the transfer of Ca 2+ microdomains to mitochondria","volume":"159","author":"Rapizzi","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0455","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1155","article-title":"Calcium signalling: dynamics, homeostasis and remodelling","volume":"4","author":"Berridge","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2019.07.002_b0460","first-page":"1047","volume":"131","author":"Clapham","year":"2007","journal-title":"Calcium Signal. Cell"},{"key":"10.1016\/j.bcp.2019.07.002_b0465","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrn.2017.170","article-title":"Mitochondria at the neuronal presynapse in health and disease","volume":"19","author":"Devine","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2019.07.002_b0470","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.bbamcr.2009.10.002","article-title":"Mitochondrial m-calpain plays a role in the release of truncated apoptosis-inducing factor from the mitochondria","volume":"1793","author":"Ozaki","year":"2009","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"key":"10.1016\/j.bcp.2019.07.002_b0475","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1113\/JP271140","article-title":"Proteolytic fragmentation of inositol 1,4,5-trisphosphate receptors: a novel mechanism regulating channel activity?","volume":"594","author":"Wang","year":"2016","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2019.07.002_b0480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/84397","article-title":"A high signal-to-noise Ca2+ probe composed of a single green fluorescent protein","volume":"19","author":"Nakai","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2019.07.002_b0485","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/ncomms5153","article-title":"Imaging intraorganellar Ca2+ at subcellular resolution using CEPIA","volume":"5","author":"Suzuki","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2019.07.002_b0490","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.febslet.2010.02.046","article-title":"Mitochondrial ion channels as therapeutic targets","volume":"584","author":"Peixoto","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2019.07.002_b0495","doi-asserted-by":"crossref","first-page":"13590","DOI":"10.1073\/pnas.0401372101","article-title":"Proapoptotic N-truncated BCL-xL protein activates endogenous mitochondrial channels in living synaptic terminals","volume":"101","author":"Jonas","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2019.07.002_b0500","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-4939-8988-1_4","article-title":"FRET-based assays to determine calpain activity","author":"McCartney","year":"2019","journal-title":"Calpain"},{"key":"10.1016\/j.bcp.2019.07.002_b0505","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuropharm.2018.01.022","article-title":"Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease","volume":"133","author":"Weber","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2019.07.002_b0510","doi-asserted-by":"crossref","first-page":"E7276","DOI":"10.1073\/pnas.1512867112","article-title":"Antifungal drug itraconazole targets VDAC1 to modulate the AMPK\/mTOR signaling axis in endothelial cells","volume":"112","author":"Head","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2019.07.002_b0515","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd3295","article-title":"Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders","volume":"9","author":"Rupprecht","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.07.002_b0520","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jbior.2014.10.001","article-title":"Role of IP3 receptor signaling in cell functions and diseases","volume":"57","author":"Mikoshiba","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.bcp.2019.07.002_b0525","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s00213-015-3997-8","article-title":"Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses","volume":"232","author":"Sahlholm","year":"2015","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.bcp.2019.07.002_b0530","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fchem.2018.00108","article-title":"VDAC1 as pharmacological target in cancer and neurodegeneration: focus on its role in apoptosis","volume":"6","author":"Magr\u00ec","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.bcp.2019.07.002_b0535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","article-title":"Role of sigma-1 receptors in neurodegenerative diseases","volume":"127","author":"Nguyen","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2019.07.002_b0540","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/1874609808666141210103146","article-title":"Translocator protein (TSPO) role in aging and Alzheimer\u2019s disease","volume":"7","author":"Repalli","year":"2014","journal-title":"Curr. Aging Sci."},{"key":"10.1016\/j.bcp.2019.07.002_b0545","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molmed.2009.01.001","article-title":"Calcium signaling and neurodegenerative diseases","volume":"15","author":"Bezprozvanny","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcp.2019.07.002_b0550","first-page":"1","article-title":"Killing two angry birds with one stone: autophagy activation by inhibiting calpains in neurodegenerative diseases and beyond","volume":"2019","author":"Weber","year":"2019","journal-title":"Biomed Res. Int."},{"issue":"1","key":"10.1016\/j.bcp.2019.07.002_b9000","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1523\/JNEUROSCI.2225-10.2011","article-title":"The mitochondrial permeability transition pore regulates nitric oxide-mediated apoptosis of neurons induced by target deprivation","volume":"31","author":"Martin","year":"2011","journal-title":"J. Neurosci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:08:24Z","timestamp":1757768904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219302576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":111,"alternative-id":["S0006295219302576"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.07.002","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}